CG
EW icon

CFO4Life Group’s Edwards Lifesciences EW Stock Holding History

CFO4Life Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,653
Closed -$311K – 224
2025
Q4 		$311K Buy
+3,653
New +$300K 0.04% 170
2021
Q4 		– Sell
-3,180
Closed -$360K – 160
2021
Q3 		$360K Buy
3,180
+300
+10% +$34.2K 0.08% 105
2021
Q2 		$298K Hold
2,880
– – 0.07% 110
2021
Q1 		$241K Hold
2,880
– – 0.06% 128
2020
Q4 		$263K Hold
2,880
– – 0.08% 122
2020
Q3 		$230K Buy
+2,880
New +$225K 0.08% 113
2020
Q1 		– Sell
-2,880
Closed -$224K – 125
2019
Q4 		$224K Hold
2,880
– – 0.09% 111
2019
Q3 		$211K Buy
+2,880
New +$202K 0.09% 112

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CFO4Life Group's EW Position: Q1 2026 in Review

CFO4Life Group sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 3,653 shares — an estimated $311K sold.

CFO4Life Group first reported a position in EW in Q3 2019 and held it in 8 quarters. The position peaked at $360K in Q3 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • CFO4Life Group reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
  • CFO4Life Group sold 3,653 Edwards Lifesciences shares in Q1 2026, an estimated $311K.
  • CFO4Life Group first reported a position in Edwards Lifesciences in Q3 2019 and held it in 8 quarters.
  • CFO4Life Group's Edwards Lifesciences position peaked at $360K in Q3 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on CFO4Life Group's 13F filing for Q1 2026, filed 11 May 2026.